{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:34Z","timestamp":1763003494450,"version":"3.45.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":599,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jtct.2021.06.022","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T02:48:21Z","timestamp":1625021301000},"page":"852.e1-852.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients"],"prefix":"10.1016","volume":"27","author":[{"given":"Roni","family":"Tamari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyajit","family":"Kosuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly A.","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris M.","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parastoo","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Castro-Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boglarka","family":"Gyurkocza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.06.022_bib0001","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: a global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2021.06.022_bib0002","first-page":"8","article-title":"Uses and growth of hematopoietic cell transplantation","author":"Horowitz","year":"2016","journal-title":"Thomas\u2019 Hematopoietic Cell Transplantation"},{"key":"10.1016\/j.jtct.2021.06.022_bib0003","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0004","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"issue":"1 suppl 1","key":"10.1016\/j.jtct.2021.06.022_bib0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2007.10.003","article-title":"Clinical strategies to enhance posttransplant immune reconstitution","volume":"14","author":"Bernstein","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/asheducation-2015.1.215","article-title":"Immune reconstitution following stem cell transplantation","volume":"2015","author":"van den Brink","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2021.06.022_bib0007","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1080\/10428194.2016.1265113","article-title":"Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant","volume":"58","author":"Goldberg","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.06.022_bib0008","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2141.2009.07985.x","article-title":"Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions","volume":"148","author":"Felfly","year":"2010","journal-title":"Br J Haematol"},{"issue":"1 suppl","key":"10.1016\/j.jtct.2021.06.022_bib0009","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2009.11.005","article-title":"The biology of allogeneic hematopoietic cell resistance","volume":"16","author":"Shizuru","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0010","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/eji.200838383","article-title":"Space-time considerations for hematopoietic stem cell transplantation","volume":"38","author":"Bhattacharya","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0011","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0012","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.022_bib0013","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0014","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood.V88.11.4383.4383","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation","volume":"88","author":"Przepiorka","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.022_bib0015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/10428194.2014.930851","article-title":"Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant","volume":"56","author":"Ceberio","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.06.022_bib0016","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bbmt.2015.07.010","article-title":"CD34-Selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse","volume":"21","author":"Tamari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0017","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0018","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0019","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0020","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3109\/10428194.2015.1121256","article-title":"Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation","volume":"57","author":"Landau","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2021.06.022_bib0021","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/petr.12670","article-title":"Administration of G-CSF from day +6 post-allogeneic hematopoietic stem cell transplantation in children and adolescents accelerates neutrophil engraftment but does not appear to have an impact on cost savings","volume":"20","author":"O'Rafferty","year":"2016","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM197701132960201","article-title":"Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection","volume":"296","author":"Storb","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.06.022_bib0023","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/jama.1983.03330330044034","article-title":"Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality","volume":"249","author":"Bortin","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2021.06.022_bib0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2008.02.005","article-title":"Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates","volume":"14","author":"Nakamura","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0025","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2009-03-208355","article-title":"Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose","volume":"114","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.022_bib0026","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V99.8.2726","article-title":"Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation","volume":"99","author":"Bittencourt","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.022_bib0027","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbmt.2009.10.004","article-title":"The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes","volume":"16","author":"Collins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0028","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2002-11-3503","article-title":"Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation","volume":"102","author":"Perez-Simon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.022_bib0029","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood.V98.12.3221","volume":"98","author":"Zaucha","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.06.022_bib0030","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.leu.2403718","article-title":"High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation","volume":"19","author":"Baron","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.06.022_bib0031","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.2006.05.5855","volume":"24","author":"Gorin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0032","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbmt.2015.07.036","article-title":"Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exphem.2004.10.012","article-title":"Perspective: fundamental and clinical concepts on stem cell homing and engraftment: a journey to niches and beyond","volume":"33","author":"Quesenberry","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0034","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12015-008-9036-y","article-title":"The paradoxical dynamism of marrow stem cells: considerations of stem cells, niches, and microvesicles","volume":"4","author":"Quesenberry","year":"2008","journal-title":"Stem Cell Rev"},{"key":"10.1016\/j.jtct.2021.06.022_bib0035","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2352-3026(17)30215-6","article-title":"Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study","volume":"5","author":"Williams","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.06.022_bib0036","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2017.07.012","article-title":"The impact of toxicities on first-year outcomes after ex vivo CD34+ -selected allogeneic hematopoietic cell transplantation in adults with hematologic malignancies","volume":"23","author":"Kosuri","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0037","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbmt.2017.08.040","article-title":"Impact of toxicity on survival for older adult patients after CD34+ selected allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.06.022_bib0038","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbmt.2017.08.033","article-title":"Effects of late toxicities on outcomes in long-term survivors of ex vivo CD34+-selected allogeneic hematopoietic cell transplantation","volume":"24","author":"Scordo","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721010253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:08:27Z","timestamp":1763003307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721010253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666636721010253"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}